We have demonstrated that three different PARPis are known to target the PARP1/2 activity, olaparib, talazoparib, and veliparib, impair the VM formation of triple negative breast cancer cells, independently of the BRCA1/2 status. The gene discussed is PARP1; the disease is triple-negative breast carcinoma.